Navigation Links
Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players
Date:7/22/2013

EXTON, Pa., July 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that U.S. payer trust in specific biosimilar manufacturers could dictate which companies will be most successful in the future biosimilar market.

The Biosimilars Advisory Service report entitled U.S. and EU Payer Perspectives finds that, when considering various types of potential biosimilar manufacturers, a greater proportion of surveyed U.S. payers place a high level of trust in large pharmaceutical companies with biologics and/or biosimilars experience compared with non-pharmaceutical companies or emerging market companies.  Not only are biosimilars that are developed by well-trusted companies significantly more likely to be reimbursed, but they are also more likely to encounter significantly fewer reimbursement restrictions than the branded agent.

Interviewed European payers believe that if biosimilars are produced to high quality standards and are approved by the European Medicines Agency, then generally their concerns associated with different types of manufacturer and country of production will be addressed. The majority of surveyed U.S. payers report that approval by the U.S. Food and Drug Administration (FDA) will be sufficient to allay some of their concerns about biosimilars. Looking at the data at the class level, a smaller proportion of payers say that FDA approval will address all of their concerns for biosimilar monoclonal antibodies and fusion proteins for chronic diseases, compared with biosimilar small recombinant proteins.

"Although the majority of surveyed U.S. payers believe that biosimilars and brands are very similar to one another with only minor, non-clinically significant differences, a large group believe that they are only somewhat similar with significant or possibly significant clinical differences," s
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
2. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
3. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
4. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Show Healthcare Payers Aren’t Taking Drug Prices Laying Down
5. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
6. Consumer Survey Indicates Mouth Guards Worsen TMJ Symptoms As Often As Significantly Improving Them – Holistic Technologies
7. U of T engineering breakthrough promises significantly more efficient solar cells
8. SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities
9. VIC Investor Network to Significantly Accelerate Technology Company Growth
10. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
11. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Regenestem Network has announced the grand opening ... Argentina. The clinic will be lead by Silvina Pastrana, ... a multidisciplinary team of medical professionals who specialize in ... office. , The new Regenestem Network members plan ... in cellular therapies, and establish Regenestem protocols to isolate ...
(Date:5/26/2015)... , May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: ... Sangamo,s president and CEO, will provide an update on the ... an overview of the company,s business strategy at 1:30pm ET ... Healthcare Conference. The conference is being held in ... be webcast live and may be accessed via a link ...
(Date:5/26/2015)... Parsippany, NJ (PRWEB) May 26, 2015 ... quality balances and scales, is set to release a ... Portfolio of quality-driven laboratory instruments. For over a century, ... reliability in weighing technology throughout the world. Now ... that has gone Beyond Weighing to include water quality ...
(Date:5/26/2015)... , 26. mája 2015 ... mene svojej rodiny prezidentom Barackovi Obamovi a Billovi ... súvislosti so stratou Dr. Rongxiang Xu , ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol pionier, ... a jeho odhodlanie v oblasti vedy a príkladné ...
Breaking Biology Technology:Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3Dr. Rongxiang Xu, O legende 2
... 2012 Reportlinker.com announces that a ... in its catalogue: , Neuroendocrine ... Market Forecast to 2019 ... Carcinoma Therapeutics - Pipeline Assessment and ...
... Advanced Biofuels, LLC announced today that the United ... Butamax Patent Number 8,178,328. The ,328 patent covers ... from recombinant microorganisms at commercial scale.  These novel ... convert sugar to isobutanol. (Logo: ...
... external bioreactor holding human cells pumped out an anti-inflammatory ... a rat with acute inflammation caused by bacterial products ... from researchers at the University of Pittsburgh School of ... findings were published today in the inaugural issue of ...
Cached Biology Technology:Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol 2Bio-hybrid device acts as 'thermostat' to control systemic inflammation in sepsis 2
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... manufacturers in China . The order value ... of + 1 000 MSEK for 2015.   Jörgen ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... nutrient-rich, blue-green algae, appeared to provide neuroprotective support ... of amyotrophic lateral sclerosis (ALS), also known as ... have found. Although more research is needed, ... clinical benefits for ALS patients. A spirulina ...
... Boston University School of Medicine (BUSM) have demonstrated that ... to maintain their pro-inflammatory response in people with type ... first time, how a loss in homeostasis in this ... associated with T2D. Barbara Nikolajczyk, PhD, an ...
... The Biophysical Society has announced the winners of its student ... at the Baltimore Convention Center in Baltimore, Maryland, March 5-9, ... on scientific merit, with priority given to those who will ... a travel grant and will be recognized at a reception ...
Cached Biology News:Blue-green algae tested for treating ALS 2Biophysical Society announces winners of 2011 Student Travel Awards 2Biophysical Society announces winners of 2011 Student Travel Awards 3Biophysical Society announces winners of 2011 Student Travel Awards 4Biophysical Society announces winners of 2011 Student Travel Awards 5
... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
... Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Polio component type I...
Biology Products: